(Q46429600)

22 December 2017

title

Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam (English)

1 reference

22 December 2017

author

Marian Majoie

2

1 reference

22 December 2017

author name string

G M P Roberts

1

1 reference

22 December 2017

L A M Leenen

3

1 reference

22 December 2017

H P Bootsma

4

1 reference

22 December 2017

A G H Kessels

5

1 reference

22 December 2017

A P Aldenkamp

6

1 reference

22 December 2017

B E Leonard

7

1 reference

22 December 2017

publication date

1 May 2005

1 reference

22 December 2017

published in

Epilepsy Behavior

1 reference

22 December 2017

volume

6

1 reference

22 December 2017

issue

3

1 reference

22 December 2017

page(s)

366-372

1 reference

22 December 2017

Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Tolerability of levetiracetam in elderly patients with CNS disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Mood effects of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Korean Topiramate Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Topiramate on ictal seizure semiology: a quantitative, randomized, low and medium dose-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Open-label adjunctive topiramate in the treatment of bipolar disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

A pilot study of topiramate as monotherapy in the treatment of acute mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Do obese depressed patients respond to topiramate? A retrospective chart review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Topiramate: preclinical evaluation of structurally novel anticonvulsant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

ucb L059, a novel anti-convulsant drug: pharmacological profile in animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Antiepileptic effects of topiramate on amygdaloid kindling in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Topiramate: a potent anticonvulsant in the amygdala-kindled rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Topiramate blocks kainate-evoked cobalt influx into cultured neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Topiramate alters excitatory synaptic transmission in mouse hippocampus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Inhibition by levetiracetam of a non-GABAA receptor-associated epileptiform effect of bicuculline in rat hippocampus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Postmarketing experience with topiramate and cognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Safety of topiramate: adverse events and relationships to dosing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

Psychiatric adverse events during vigabatrin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2005.01.005

10.1016/J.YEBEH.2005.01.005

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

PubMed ID

15820345

1 reference

22 December 2017